2nd SOHO Italian Conference

Login

Password

Forgot your password?

Join VuMedi

Select specialty

First name

Last name

Choose Password

About Us
Careers
Partner with us
F.A.Q
Contact us
Terms & conditions
Privacy policy

2nd SOHO Italian Conference

http://www.sohoitaly.it/

Lymphoma
Leukemia
Myeloma
MDS
COVID-19
Event

Playback speed

10 seconds

How I Treat Frontline CML: What Are the Differences in ELTS vs. Sokal’s Risk Score? Does Imatinib OS Differ in High/Intermediate/Low-Risk Patients? Should We Discontinue TKIs in Some Groups?

By 2nd SOHO Italian Conference FEATURING Giuseppe Saglio

0 views

January 27, 2021

Comments 0

A proven CD123 targeted therapy for BPDCN

Feat. H. Erba

Targeting CSF-1R to Manage Inflammation and Fibrosis in GVHD

Leukemia

14:51

2nd SOHO Italian Conference

MRD & ALL Management: What Role Does It Play in AlloHSCT Setting?

Feat. A. Rambaldi

17:00

2nd SOHO Italian Conference

How I Treat AML at MD Anderson: ATRA & GO Combos, Sequential HD …

Feat. H. Kantarjian

09:43

2nd SOHO Italian Conference

MD Anderson Future Directions in AML: Efficacy of FLT3 / IDH Inhibit…

Feat. H. Kantarjian

10:02

2nd SOHO Italian Conference

How I Treat ALL at MD Anderson: What Hyper-CVAD Combinations Showed …

Feat. H. Kantarjian

13:11

2nd SOHO Italian Conference

MD Anderson Future Directions in ALL: How Effective Are New Blina/In…

Feat. H. Kantarjian

13:38

2nd SOHO Italian Conference

TFR and CML: Why Is TFR Important? What Happens After? Why Is It Dif…

Feat. E. Abruzzese

08:52

2nd SOHO Italian Conference

TFR in CML: What Are the Influencing Factors? Do Patients Lose MR Af…

Feat. M. Malagola

14:09

2nd SOHO Italian Conference

How I Treat Frontline CML: What Are the Differences in ELTS vs. Soka…

Feat. G. Saglio

09:15

2nd SOHO Italian Conference

Post-SCT Maintenance in AML: What Is the Role of Hypomethylating Age…

Feat. A. Sperotto

15:37

2nd SOHO Italian Conference

Allogenic Transplant in AML: How Does ASCT Compare to Chemo in Older…

Feat. A. Olivieri

13:56

2nd SOHO Italian Conference

MRD Assessment in Frontline AML: What Are the Characteristics of Dif…

Feat. F. Buccisano

09:22

2nd SOHO Italian Conference

Prognostic Relevance of BPDCN-Like Phenotype in Newly Diagnosed AML:…

Feat. R. Lemoli

11:45

2nd SOHO Italian Conference

Pro-Apoptotic Pathways in AML: How Does Venetoclax Work in Combinati…

Feat. S. Galimberti

14:40

2nd SOHO Italian Conference

Genomic Sequencing in AML and MDS: How Can We Define Subtypes and Mu…

Feat. I. Iacobucci

12:17

2nd SOHO Italian Conference

Novel mAbs in ALL: Is Ino Better than SoC? What Is the MRD-Negativit…

Feat. F. Lanza

10:44

2nd SOHO Italian Conference

mAbs in ALL: Does Blinatumomab Prolong Survival in R/R Ph+/- Disease…

Feat. C. Papayannidis

08:04

2nd SOHO Italian Conference

Cell Morphology in Acute Leukemias & Hematologic Malignancies: D…

Feat. G. Zini

11:05

2nd SOHO Italian Conference

Synthetic Lethality Against ALL: How Often Is the Expression of DDR-…

Feat. A. Ghelli Luserna Di Rora

14:43

2nd SOHO Italian Conference

2020 SOHO Update on R/R ALL: Is CD19-Targeted CAR-T Beneficial for O…

Feat. J. Ribera

16:49

2nd SOHO Italian Conference

2020 SOHO Updates on ALL: Does Ponatinib+Steroids Help Induce CHR in…

Feat. G. Martinelli

11:57

2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: Does CPX-351 Increase OS a…

Feat. C. Cerchione

10:44

2nd SOHO Italian Conference

2020 SOHO Updates on AML: Is Targeting CAMDR a New Frontier? Can E-S…

Feat. C. Cerchione

18:18

2nd SOHO Italian Conference

MD Anderson State of the Art in CLL Treatment: What Is Changing and …

Feat. A. Ferrajoli

10:10

2nd SOHO Italian Conference

2020 SOHO Updates on Newly Diagnosed AML: What Is the ORR With Aza v…

Feat. A. de la Fuente

16:49

2nd SOHO Italian Conference

2020 SOHO Update on Ph-Like ALL: How Important Are Genomic Alteratio…

Feat. M. Konopleva

19:30

2nd SOHO Italian Conference

2020 SOHO Update on AML in Older Patients at MD Anderson: Therapy In…

Feat. T. Kadia

22:54

2nd SOHO Italian Conference

2020 SOHO Update on MPN: Ruxolitinib vs. BAT in ET, Ruxolitinib in P…

Feat. S. Verstovsek

18:07

2nd SOHO Italian Conference

2020 SOHO Update on Diagnostic Approaches to Ph-Like B-ALL: CRLF2 De…

Feat. S. Konoplev

09:51

2nd SOHO Italian Conference

2020 SOHO Update on FLT3+ AML: What Are the Novel FLT3 Inhibitors? H…

Feat. N. Daver

14:15

2nd SOHO Italian Conference

2020 SOHO Update on Immunotherapy in AML: Gemtuzumab Ozogamicin Plus…

Feat. N. Daver

16:36

2nd SOHO Italian Conference

How I Manage CML at MD Anderson in 2020: How Effective & Safe Is…

Feat. E. Jabbour

13:05

2nd SOHO Italian Conference

2020 SOHO Update on Frontline Therapy Optimization in ALL: How Effec…

Feat. E. Jabbour

10:43

2nd SOHO Italian Conference

2020 SOHO Update on Frontline MDS: What Is the Role of Genomic Annot…

Feat. G. Garcia-Manero

12:20

2nd SOHO Italian Conference

2020 SOHO Update on Antibodies in AML: Is Gemtuzumab Ozogamicin Effe…

Feat. F. Ravandi

12:54

2nd SOHO Italian Conference

2020 SOHO Update on Maintenance AML: Does It Improve Clinical Outcom…

Feat. F. Ravandi